EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis

Ali A Habib iD, Michael Benatar, Tuan Vu, Andreas Meisel iD, Shahram Attarian, Masahisa Katsuno iD, Serena Liao, Kathleen N Beasley, James F Howard iD

European Journal of Neurology · 2024-12 · 31 (12)

DOI: 10.1111/ene.16490 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Neurology, online erschienen am 07.10.2024. Verfasst von Ali A Habib und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Irvine, California, USA. Hauptthemen laut MEDLINE: Myasthenia Gravis, Receptors, Cholinergic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Alexion Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The efficacy and safety of ravulizumab, a terminal complement C5 inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive (AChR Ab+) generalized myasthenia gravis (gMG) were demonstrated in the CHAMPION MG study (NCT03920293). This analysis aimed to characterize the latency to onset of a clinically meaningful therapeutic effect for ravulizumab.

Methods

Post hoc analysis of data collected for up to 60 weeks from CHAMPION MG was performed to assess the timing of response to ravulizumab. Response was analyzed based on reductions of ≥2 and ≥3 points (minimal clinically important differences [MCIDs]) in Myasthenia Gravis–Activities of Daily Living (MG‐ADL) and Quantitative Myasthenia Gravis (QMG) total scores, respectively, and on more rigorous reductions of ≥3 and ≥5 points, respectively. Time to first response was assessed using the Kaplan–Meier product‐limit method.

Results

The median (95% confidence interval) time to first response was 2.1 (2.1–2.6) and 4.1 (2.3–10.0) weeks for reductions of ≥2 and ≥3 points in MG‐ADL total score, respectively ( n = 139), and 4.1 (2.1–10.0) and 18.3 (11.0–33.4) weeks for reductions of ≥3 and ≥5 points in QMG total score, respectively ( n = 134). Cumulative response rates at Week 60 (data cut‐off) were 88% and 82% for ≥2‐ and ≥3‐point MG‐ADL score reductions, respectively, and 86% and 59% for ≥3‐ and ≥5‐point QMG score reductions, respectively.

Conclusions

The median times to MCID with ravulizumab treatment in patients with AChR Ab+ gMG were ~2 weeks and ~4 weeks based on MCID MG‐ADL and QMG total score reductions, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisReceptors, CholinergicAntibodies, Monoclonal, HumanizedHumansFemaleMaleAdultMiddle AgedComplement Inactivating AgentsAgedAutoantibodiesTreatment OutcomeDouble-Blind MethodTime Factors

Stichwörter der Autor:innen

activities of daily livingcomplement inactivating agentsmuscle strengthmyasthenia gravis, generalized

Substanzen

Receptors, CholinergicAntibodies, Monoclonal, HumanizedComplement Inactivating AgentsAutoantibodies

Autor:innen und Institutionen

  • University of California, Irvine, California, USA.
  • Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
  • Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Reference Center for Neuromuscular Disorders and Amyotrophic Lateral Sclerosis, CHU La Timone, Aix-Marseille Université, Marseille, France.
  • Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ORCID-Profile: Ali A Habib, Andreas Meisel, Masahisa Katsuno, James F Howard

Förderung

  • Alexion, AstraZeneca Rare Disease
  • Alexion Pharmaceuticals

Zitieren

APA

Habib, A. A., Benatar, M., Vu, T., Meisel, A., Attarian, S., Katsuno, M., Liao, S., Beasley, K. N., & Howard, J. F. (2024). Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis. European Journal of Neurology, 31(12). https://doi.org/10.1111/ene.16490

Vancouver

Habib AA, Benatar M, Vu T, Meisel A, Attarian S, Katsuno M, et al. Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis. European Journal of Neurology. 2024;31(12). doi:10.1111/ene.16490

BibTeX
@article{Habib2024,
  author = {Habib, Ali A and Benatar, Michael and Vu, Tuan and Meisel, Andreas and Attarian, Shahram and Katsuno, Masahisa and Liao, Serena and Beasley, Kathleen N and Howard, James F},
  title = {Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {12},
  doi = {10.1111/ene.16490}
}
Kostenlos starten →